Xencor (XNCR) Earns Buy Rating from Piper Jaffray Companies

Xencor (NASDAQ:XNCR)‘s stock had its “buy” rating reaffirmed by stock analysts at Piper Jaffray Companies in a research report issued on Sunday, November 12th. They presently have a $35.00 target price on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price objective points to a potential upside of 62.87% from the stock’s previous close.

Several other brokerages have also recently commented on XNCR. ValuEngine cut Xencor from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. Canaccord Genuity set a $36.00 target price on Xencor and gave the company a “buy” rating in a report on Monday, October 23rd. BidaskClub cut Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, Zacks Investment Research cut Xencor from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $30.80.

Shares of Xencor (NASDAQ XNCR) traded down $0.22 during mid-day trading on Friday, hitting $21.49. The stock had a trading volume of 190,460 shares, compared to its average volume of 216,573. Xencor has a twelve month low of $18.55 and a twelve month high of $29.38.

In other Xencor news, major shareholder John S. Stafford III purchased 150,000 shares of the stock in a transaction dated Friday, October 27th. The stock was acquired at an average cost of $19.81 per share, for a total transaction of $2,971,500.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder John S. Stafford III bought 15,374 shares of the firm’s stock in a transaction that occurred on Tuesday, November 28th. The shares were purchased at an average cost of $19.86 per share, for a total transaction of $305,327.64. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 263,105 shares of company stock valued at $5,206,858. Company insiders own 4.14% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC lifted its stake in Xencor by 77.7% during the 2nd quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock worth $141,232,000 after acquiring an additional 2,924,510 shares in the last quarter. Vanguard Group Inc. lifted its stake in Xencor by 5.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock worth $35,913,000 after acquiring an additional 90,094 shares in the last quarter. State Street Corp lifted its stake in Xencor by 11.1% during the 2nd quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock worth $23,295,000 after acquiring an additional 110,474 shares in the last quarter. Northern Trust Corp lifted its stake in Xencor by 6.6% during the 2nd quarter. Northern Trust Corp now owns 498,616 shares of the biopharmaceutical company’s stock worth $10,527,000 after acquiring an additional 30,715 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Xencor by 8.0% during the 1st quarter. Geode Capital Management LLC now owns 367,230 shares of the biopharmaceutical company’s stock worth $8,783,000 after acquiring an additional 27,099 shares in the last quarter. 77.61% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was published by BBNS and is the sole property of of BBNS. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://baseballnewssource.com/markets/piper-jaffray-companies-reiterates-buy-rating-for-xencor-inc-xncr/1779386.html.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan


Leave a Reply

 
© 2006-2017 BBNS.